An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced ovarian cancer


The aim of this systematic review is to update the previous systematic review by bringing together the most recent reliable data to elucidate the following area of uncertainty: the use of paclitaxel as first-line treatment of ovarian cancer.


The evidence does not appear to support the use of paclitaxel as first-line therapy for advanced ovarian cancer, and may provide a case for considering the use of carboplatin as first-line treatment for advanced ovarian cancer, rather than taxanes.

Conducted by: CRD

Further details

Project page on HTA Programme website

Related guidance

Commissioned to inform NICE Technology Appraisal 55: Review of the clinical effectiveness and cost effectiveness of paclitaxel for ovarian cancer. London: National Institute for Clinical Excellence; 2003. NB: This appraisal has been reviewed and the guidance replaced by Ovarian cancer - paclitaxel (review) (No 55)


Commissioned by the HTA Programme on behalf of NICE's Technology Assessment Report (TAR) process